New User? Sign Up Free
SCCM is performing maintenance on its websites. For the best browsing experience, please use Microsoft Edge or Safari. Those using Chrome or Firefox may experience access issues at this time.
The Centers for Disease Control and Prevention (CDC) Nowcast data from April 5, 2022, estimates that the proportion of COVID-19 cases caused by the Omicron BA.2 variant is above 50% in all Health and Human Services (HHS) U.S. regions. Data included in the health care provider fact sheet show the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant. Due to these data, sotrovimab is not authorized in any U.S. state or territory at this time.
On April 14, 2022, the FDA revised the Emergency Use Authorization (EUA) for the COVID-19 oral antiviral therapeutic Paxlovid to authorize an additional dose pack presentation with appropriate dosing for patients with moderate renal impairment within the scope of the EUA. As a result, Paxlovid will soon be available in two package presentations.
Frederick P. Ognibene, MD, FCCM, discusses his goals as the Society's president for 2007 as well as his decades-long involvement in SCCM and the critical care community.
Gregory Martin, MD, discusses some of the topics from his presentation during the 36th Critical Care Congress, "Furosemide and Albumin in ARDS."
Djillali Annane, MD, discusses a study on epinephrine versus norepinephrine for septic shock he presented during the 36th Critical Care Congress.
Paul Marik, MD, FCCM, discusses the June Critical Care Medicine article, "Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements from an International Task Force by the American College of Critical Care Medicine."
Joseph F. Dasta, MSc, FCCM, discusses his article published in the February 2010 issue of Critical Care Medicine, titled “A Cost Minimization Analysis of Dexmedetomidine Compared with Midazolam for Long-Term Sedation in the Intensive Care Unit.”
Matthew C. Scanlon, MD, discuses is article, “Value of Human Factors to Medication and Patient Safety in the Intensive Care Unit,” published as part of a supplement to the June 2010 issue of Critical Care Medicine.
Jerry J. Zimmerman, MD, PhD, FCCM, discusses his article published in the January Pediatric Critical Care Medicine, titled “Adjunctive Corticosteroid Therapy in Pediatric Severe Sepsis: Observations From the RESOLVE.”
Margaret Parker, MD, MCCM, speaks with Katherine J. Steineck, PharmD, pediatric clinical pharmacist at the University of Minnesota Amplatz Children’s Hospital. They discuss the article published in Pediatric Critical Care Medicine, “Evaluation of a Pharmacist-Managed Methadone Taper.” I
Todd Fraser, MD, speaks with Daniel F. McAuley, MD, about his article, “Simvastatin in the Acute Respiratory Distress Syndrome,” published in the October 2014 New England Journal of Medicine.
Margaret Parker, MD, MCCM, speaks with Nnenna O. Chime, MD, MPH, about the article, “A Survey Demonstrating Lack of Consensus on the Sequence of Medications for Treatment of Hyperkalemia among Pediatric Critical Care Providers,” published in the June 2015 issue of Pediatric Critical Care Medicine.
Margaret Parker, MD, MCCM, speaks with Steven L. Shein, MD, about the article, “Effectiveness of Pharmacological Therapies for Intracranial Hypertension in Children With Severe Traumatic Brain Injury—Results From an Automated Data Collection System Time-Synched to Drug Administration,” published in the March 2016 issue of Pediatric Critical Care Medicine.
Margaret Parker, MD, MCCM, speaks with Mary Jo C. Grant, APRN, PhD, about the article, “Dexmedetomidine Use in Critically-Ill Children with Acute Respiratory Failure,” published in the December 2016 issue of Pediatric Critical Care Medicine.
Ludwig Lin, MD, speaks with Palash Kar, MBBS, about the article, “Liberal Glycemic Control in Critically Ill Patients With Type 2 Diabetes: An Exploratory Study," published in Critical Care Medicine.
Continuous renal replacement therapy (CRRT) is complex, and dosing varies among institutions. Review dosing regimens, utilization in COVID-19 patients, and more in this podcast.
Although several trials have examined in-hospital cardiac arrest (IHCA), only two trials in the past decade have examined the use of vasopressin and glucocorticoids for IHCA. Both trials found improved survival and favorable neurologic outcome with a vasopressin-epinephrine-methylprednisolone combination. Because of a lack of additional supporting evidence, neither the American nor European international guidelines have recommended this combination for IHCA. This Concise Critical Appraisal examines an article by Andersen et al that attempted to validate the results of these trials.
Stay up to date on the mass vaccination efforts in the United States with this SCCM webcast. Thought leaders will address current COVID-19 variants and vaccine efficacy and review pediatric vaccination considerations. This webcast is the second in a series of updates that SCCM is producing to better educate clinicians as vaccination efforts continue. The webinar was held on December 8, 2021.
Two recent trials suggest that immune-damping drugs such as tocilizumab may reduce mortality in patients with severe COVID-19.
This Concise Critical Appraisal offers a deep dive into the HALT-IT trial, which investigated whether early use of tranexamic acid to treat acute severe gastrointestinal bleeds would reduce overall mortality while limiting the burden of thromboembolic events.
Villar et al (Lancet Respir Med. 2020;8:267-276) attempted to demonstrate the effect of steroids in patients with moderate to severe acute respiratory distress syndrome (ARDS) along with modern standard ICU practices, including lung-protective mechanical ventilation.
Girard et al (N Engl J Med. 2018;379:2506-2516) and Page et al (Lancet Respir Med. 2013;1:515-523) evaluated the treatment of acute delirium with antipsychotics.
Crit Care Med 2017; 45(9):e877-e915